Cancer overtakes heart disease as leading cause of death in 22 U.S. states

Since the 1940s, heart disease has held a dubious distinction as the leading cause of death in the United States, with cancer consistently placing second in terms of overall mortality.

But due to a sharp decrease in deaths resulting from cardiovascular disease, cancer has narrowed the gap and is challenging for the title of the nation’s number-one cause of mortality, according to research published online by the American Heart Association.

Researchers from Brigham Young University in Provo, Utah, set out to investigate whether cancer’s transition from runner-up to leading cause of death had already begun to take place around the country. They analyzed state-specific mortality data from the U.S. National Vital Statistics System and determined mortality rate ratios of heart disease and cancer for each state from 1999 to 2013 on an annual basis.

The found that during that time period, mortality as a result of heart disease fell from a rate of 266 to 193 per 100,000 nationwide, while national cancer mortality fell from 201 to 185 per 100,000, resulting in a total heart disease/cancer mortality rate ration decrease from 1.32 to 1.04.

Many states saw cancer overtake heart disease as the leading cause of death over the same 14-year period, however, with the transition taking place in 22 states since 1999.

“Due to rapidly declining [heart disease] mortality rates, the transition from [heart disease] to cancer as the leading cause of death has already occurred in nearly half of U.S. states,” the researchers wrote. “National-level data mask this reality, implying an oversimplified public health message that ‘[heart disease] is the leading cause of death.’ State-specific data highlight successes in CVD prevention and control and the need for further improvements in cancer prevention and control.”

 

John Hocter,

Digital Editor

With nearly a decade of experience in print and digital publishing, John serves as Content Marketing Manager. His professional skill set includes feature writing, content marketing and social media strategy. A graduate of The Ohio State University, John enjoys spending time with his wife and daughter, along with a number of surprisingly mischievous indoor cacti.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.